PPARGC1A and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Our results indicate that inhibitors of mitochondrial function or PPARGC1A could be efficiently utilized as monotherapy or combination therapy for treating tRCC.